3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Conditions
Lymphoma
142
Leukemia
111
Leukemia, Myeloid, Acute
100
Precursor Cell Lymphoblastic Leukemia-Lymphoma
93
Lymphoma, Non-Hodgkin
91
Multiple Myeloma
88
Lymphoma, Large B-Cell, Diffuse
80
Myelodysplastic Syndromes
74
Lymphoma, Follicular
73
Lymphoma, Mantle-Cell
72
Leukemia, Lymphocytic, Chronic, B-Cell
69
Burkitt Lymphoma
67
Hodgkin Disease
66
Lymphoma, Large-Cell, Immunoblastic
60
Lymphoma, B-Cell, Marginal Zone
49
Breast Neoplasms
48
Neoplasms, Plasma Cell
39
Leukemia, Myeloid, Accelerated Phase
34
Leukemia, Myeloid, Chronic-Phase
33
Recurrence
32
Myeloproliferative Disorders
32
Ovarian Neoplasms
31
Congenital Abnormalities
30
Blast Crisis
30
Sarcoma
28
Dendritic Cell Sarcoma, Interdigitating
28
Central Nervous System Neoplasms
28
Leukemia, Myelomonocytic, Chronic
27
Neuroblastoma
25
Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative
21
Interventions
Rituximab
7
Valganciclovir
5
Valacyclovir
3
Gemcitabine
3
Dexamethasone
3
Cisplatin
3
spartalizumab
2
pegaspargase
2
Radiotherapy, Intensity-Modulated
2
Methylprednisolone
2
Lenalidomide
2
Etoposide
2
Doxorubicin
2
Cell Count
2
Blood Specimen Collection
2
valomaciclovir
1
toripalimab
1
ruxolitinib
1
pembrolizumab
1
merphos
1
fludarabine
1
dehydroftorafur
1
avelumab
1
apatinib
1
Zidovudine
1
Watchful Waiting
1
Valproic Acid
1
Vaccines
1
Tenofovir
1
Tegafur
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Epstein-Barr Virus Infections
×
Filgrastim
×
Clear all
NCT00953420
2017-08-18
CADEN
Baylor College of Medicine
Phase 2
Completed
20 enrolled